AVIR – atea pharmaceuticals, inc. - common stock (US:NASDAQ)

News

Atea Pharmaceuticals (NASDAQ:AVIR) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... [Yahoo! Finance]
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript [Seeking Alpha]
Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com